PT - JOURNAL ARTICLE AU - Alexandre B Cavalcanti AU - Fernando G Zampieri AU - Luciano CP Azevedo AU - Regis Rosa AU - Álvaro Avezum AU - Viviane C Veiga AU - Renato D. Lopes AU - Letícia Kawano-Dourado AU - Lucas P Damiani AU - Adriano J Pereira AU - Ary Serpa-Neto AU - Remo Furtado AU - Bruno Tomazini AU - Fernando A Bozza AU - Israel S. Maia AU - Maicon Falavigna AU - Thiago C Lisboa AU - Henrique Fonseca AU - Flávia R Machado AU - Otavio Berwanger AU - for the COALITION COVID-19 Brasil I Investigators TI - Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial AID - 10.1101/2020.05.19.20106997 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.19.20106997 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106997.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106997.full AB - Introduction Hydroxychloroquine and its combination with azithromycin have been suggested to improve viral clearance in patients with COVID-19, but its effect on clinical outcomes remains uncertain.Methods and analysis We describe the rationale and design of an open-label pragmatic multicentre randomised (concealed) clinical trial of 7 days of hydroxychloroquine (400 mg BID) plus azithromycin (500 mg once daily), hydroxychloroquine 400 mg BID, or standard of care for moderately severe hospitalised patients with suspected or confirmed COVID-19 (in-patients with up to 4L/minute oxygen supply through nasal catheter). Patients are randomised in around 50 recruiting sites and we plan to enrol 630 patients with COVID-19. The primary endpoint is a 7-level ordinal scale measured at 15-days: 1)not hospitalised, without limitations on activities; 2)not hospitalised, with limitations on activities; 3)hospitalised, not using supplementary oxygen; 4)hospitalised, using supplementary oxygen; 5)hospitalised, using high-flow nasal cannula or non-invasive ventilation; 6)hospitalised, on mechanical ventilation; 7)death. Secondary endpoints are the ordinal scale at 7 days, need for mechanical ventilation and rescue therapies during 15 days, need of high-flow nasal cannula or non-invasive ventilation during 15 days, length of hospital stay, in-hospital mortality, thromboembolic events, occurrence of acute kidney injury, and number of days free of respiratory support at 15 days. Secondary safety outcomes include prolongation of QT interval on electrocardiogram, ventricular arrhythmias, and liver toxicity. The main analysis will consider all patients with confirmed COVID-19 in the groups they were randomly assigned.Ethics and dissemination This study has been approved by Brazil’s National Ethic Committee (CONEP) and National Health Surveillance Agency (ANVISA). An independent data monitoring committee will perform interim analyses and evaluate adverse events throughout the trial. Results will be submitted for publication after enrolment and follow-up are complete, as well as presented and reported to local health agencies.ClinicalTrials.gov identifier NCT04322123Strengths and limitations of this studyPragmatic randomised controlled trial of 7 days of hydroxychloroquine plus azithromycin, hydroxychloroquine or standard of care for moderately severe in-patients with suspected or confirmed COVID-19Multicentre: around 50 recruiting sites in Brazil with planned enrolment of 630 patients (1:1:1)The primary endpoint is a 7-level ordinal scale ([1] not hospitalised, without limitations on activities; [2] not hospitalised, with limitations on activities; [3] hospitalised, not using supplementary oxygen; [4] hospitalised, using supplementary oxygen; [5] hospitalised, using high-flow nasal cannula or non-invasive ventilation; [6] hospitalised, on mechanical ventilation; [7] death) measured at 15 days.Open label design (no placebo)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04322123Funding StatementThis trial was funded by Associação Beneficente Síria - HCor. EMS Pharmaceutical provided partial funding, the study drugs and logistics for the trial but was not involved in study design, conduct, analysis, or decision to publish these results. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol paper. No data is provided.